Search - tctmd.com

Displaying 881 - 900 of 901

Presentation TCT 2012

Response to Prasugrel in ST Elevation Myocardial Infarction Patients: is it as Rapid as we Expected?

Presenter: Fr?d?ric Casassus, Lionel Leroux, Chloe James, Sali Sidibe, Agnalys Desplantes, David Naibo, Benjamin Seguy, Pierre Chevallereau, Pierre Coste

January 03, 2012

Presentation TCT 2012

Protease Activated Receptor-1 (PAR-1) Mediated Platelet Aggregation is Dependant on Clopidogrel Response

Presenter: Rolf P. Kreutz, David A. Flockhart, Yvonne Kreutz, Jeffrey A. Breall

January 03, 2012

Presentation TCT 2012

Prolonged Bivalirudin Infusion is Associated with Enhanced ST Segment Resolution Following Primary Percutaneous Coronary Intervention

Presenter: Bernardo Cortese, Ugo Limbruno, Sara De Matteis, Livia Diehl, Antonino Pit?

January 03, 2012

Presentation TCT 2012

<b>Pharmacodynamic Effect of Double-dose Clopidogrel versus Adding Dipyridamole In Patients With High On-treatment Platelet Reactivity (ACCEL-DIP) study</b>

Presenter: Yongwhi Park, Young-Hoon Jeong, Jeong-Rang Park, Seok-Jae Hwang, Choong Hwan Kwak, Jin-Yong Hwang

January 03, 2012

Presentation TCT 2012

Paraoxonase-1 (PON1) Activity And PON1 Polymorphisms Have No Effect On Platelet Reactivity In Patients Treated With Clopidogrel

Presenter: Jean-Pierre P. Dery, Abdelouahed Khalil, Ugo D?ry, M?lanie Roy, Pierluigi Tricoci, Richard Becker, Stéphane Rinfret, Éric Larose, G?rald Barbeau, Robert DeLarochelli?re, Josep Rod?s-Cabau, Olivier F. Bertrand

January 03, 2012

Presentation TCT 2012

Methods of measurement of aspirin-mediated antiplatelet. Degree of correlation and agreement between two “point of care: VerifyNow®Aspirin assay and PFA-100®

Presenter: Jose Maria Cubero Gomez, Maria Asunci?n Navarro Puerto, Maria Isabel De Mier Barragan, Francisco J. Sanchez-Burguillos, Pastor L. Perez-Santigosa, Francisco J. Molano Casimiro, Luis F. Pastor Torres

January 03, 2012

Presentation TCT 2012

Long-Term Dual Anti-Platelet Therapy in Patients Treated with Bare Metal Stent Implantation: Results From the NHLBI Dynamic Registry

Presenter: Gopi Manthripragada, Oscar C. Marroquin, Helen Vlachos, Sameer Khandhar, Catalin Toma, Joon S. Lee, David O. Williams, Kevin E. Kip, Suresh Mulukutla

January 03, 2012

Presentation TCT 2012

Inhibition of Platelet Aggregation by Prostaglandin E1 (PGE1) May Be Attenuated in Diabetic Patients During Therapy with Clopidogrel

Presenter: Rolf P. Kreutz, Perry Nystrom, Yvonne Kreutz, Jiao Miao, Richard Kovacs, David Flockhart, Zeruesenay Desta, Yan Jin

January 03, 2012

Presentation TCT 2012

In hospital and 30 day outcomes in all-comer percutaneous coronary intervention with bivalirudin: Initial report of the prospective EUROVISION Registry. Hamon M, Nienaber C,...

Presenter: Martial Hamon

January 03, 2012

Presentation TCT 2012

Genetic Variants Affecting Clopidogrel Metabolism Have Minor Influence on Platelet Reactivity After Elective Percutaneous Coronary Intervention

Presenter: Andr?s Kom?csi, Orsolya Rideg, Gy?ngyv?r K?lt?, Andr?s Vorobcsuk, Daniel Aradi

January 03, 2012

Presentation TCT 2012

Genetic Determinants of Clopidogrel Responsiveness in Koreans

Presenter: Jin Joo Park, Kyung Woo Park, Jeehoon Kang, Ki-Hyun Jeon, Si-Hyuk Kang, Hyo Suk Ahn, Han-Mo Yang, Hae-Young Lee, Hyun-Jae Kang, Bon-Kwon Koo, Byung-Hee Oh, Young-Bae Park, Hyo-Soo Kim

January 03, 2012

Presentation TCT 2012

Evaluation of Dose Requirements for Prolonged Bivalirudin Administration in Patients with Renal Insufficiency and Suspected Heparin-Induced Thrombocytopenia.

Presenter: James W. Wisler, Jeffrey B. Washam, Richard C. Becker

January 03, 2012

Presentation TCT 2012

CYP3A4 Genetic Status May Be Associated with Increased Vulnerability to the Adverse Effect of Calcium Channel Blockers on Clopidogrel Response Variability

Presenter: Jin Joo Park, Kyung Woo Park, Jeehoon Kang, Ki-Hyun Jeon, Si-Hyuk Kang, Hyo Suk Ahn, Han-Mo Yang, Hae-Young Lee, Hyun-Jae Kang, Bon-Kwon Koo, Byung-Hee Oh, Young-Bae Park, Hyo-Soo Kim

January 03, 2012

Presentation

CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events

Presenter: Michael V. Holmes

January 03, 2012

Presentation TCT 2012

Comparison of bivalirudin versus heparin during PCI in patients receiving prasugrel M Hamon, S Marso, SV Rao, M Valgimigli, F Verheugt, A Gershlick, Y Wang, GP Steg, E...

Presenter: Martial Hamon

January 03, 2012

Presentation TCT 2012

Clopidogrel Hyporesponsiveness, Interacting with Diabetes Mellitus, Predicts 2-Year Cardiovascular Outcome Among Taiwanese Population Underging Percutaneous Coronary Intervention

Presenter: Ping-Yen Liu, Ling-Jay Hsu, Po-Tseng Lee, Cheng-Hann Lee, Ju-Yi Chen, Yi-Heng Li, Liang-Miin Tsai, Jyh-Hong Chen

January 03, 2012

Presentation TCT 2012

Clinical Outcomes Of Intracoronary Eptifibatide Bolus-only versus Intracoronary Bolus and Intravenous Infusion of Eptifibatide in Primary Percutaneous Coronary Intervention

Presenter: Dinna K. Soon, Hee Hwa Ho, Kwok Kong Loh, Yau Wei Ooi, David Foo, Paul Ong, Fahim Jafary

January 03, 2012

Presentation TCT 2012

Bivalirudin Use During Percutaneous Coronary Intervention Improves Clinical and Economic Outcomes in Diabetic Women

Presenter: Erin M. Galbraith, Roxana Mehran, Chandan Devireddy, Henry A. Liberman, Steven V. Manoukian, Michele D. Voeltz

January 03, 2012

Presentation TCT 2012

Benefits of CD 34 Antibody Coated Stent in Patients with High Risk for Bleeding During Dual Antiplatelet Therapy.

Presenter: Miltiadis Papalexandris, Hubertus Degen, Carsten Stoepel, Thomas Lickfeld, Thorsten Schneider, Carlos Freitas, Michael Haude

January 03, 2012

Presentation TCT 2012

Atorvastatin, Administered at the Onset of Reperfusion, Protects Human Myocardium Against Lethal Reperfusion Injury by Activation of the RISK pathway

Presenter: Paul S. Rees, Derek J. Hausenloy, Derek M. Yellon

January 03, 2012

Advertisement

Response to Prasugrel in ST Elevation Myocardial Infarction Patients: is it as Rapid as we Expected?

Protease Activated Receptor-1 (PAR-1) Mediated Platelet Aggregation is Dependant on Clopidogrel Response

Prolonged Bivalirudin Infusion is Associated with Enhanced ST Segment Resolution Following Primary Percutaneous Coronary Intervention

<b>Pharmacodynamic Effect of Double-dose Clopidogrel versus Adding Dipyridamole In Patients With High On-treatment Platelet Reactivity (ACCEL-DIP) study</b>

Paraoxonase-1 (PON1) Activity And PON1 Polymorphisms Have No Effect On Platelet Reactivity In Patients Treated With Clopidogrel

Methods of measurement of aspirin-mediated antiplatelet. Degree of correlation and agreement between two “point of care: VerifyNow®Aspirin assay and PFA-100®

Long-Term Dual Anti-Platelet Therapy in Patients Treated with Bare Metal Stent Implantation: Results From the NHLBI Dynamic Registry

Inhibition of Platelet Aggregation by Prostaglandin E1 (PGE1) May Be Attenuated in Diabetic Patients During Therapy with Clopidogrel

In hospital and 30 day outcomes in all-comer percutaneous coronary intervention with bivalirudin: Initial report of the prospective EUROVISION Registry. Hamon M, Nienaber C,...

Genetic Variants Affecting Clopidogrel Metabolism Have Minor Influence on Platelet Reactivity After Elective Percutaneous Coronary Intervention

Genetic Determinants of Clopidogrel Responsiveness in Koreans

Evaluation of Dose Requirements for Prolonged Bivalirudin Administration in Patients with Renal Insufficiency and Suspected Heparin-Induced Thrombocytopenia.

CYP3A4 Genetic Status May Be Associated with Increased Vulnerability to the Adverse Effect of Calcium Channel Blockers on Clopidogrel Response Variability

CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events

Comparison of bivalirudin versus heparin during PCI in patients receiving prasugrel M Hamon, S Marso, SV Rao, M Valgimigli, F Verheugt, A Gershlick, Y Wang, GP Steg, E...

Clopidogrel Hyporesponsiveness, Interacting with Diabetes Mellitus, Predicts 2-Year Cardiovascular Outcome Among Taiwanese Population Underging Percutaneous Coronary Intervention

Clinical Outcomes Of Intracoronary Eptifibatide Bolus-only versus Intracoronary Bolus and Intravenous Infusion of Eptifibatide in Primary Percutaneous Coronary Intervention

Bivalirudin Use During Percutaneous Coronary Intervention Improves Clinical and Economic Outcomes in Diabetic Women

Benefits of CD 34 Antibody Coated Stent in Patients with High Risk for Bleeding During Dual Antiplatelet Therapy.

Atorvastatin, Administered at the Onset of Reperfusion, Protects Human Myocardium Against Lethal Reperfusion Injury by Activation of the RISK pathway

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content